Industry news

Adimab issues a challenge: Use new tech to build a rapid-response R&D platform for infectious diseases

John Carroll / FierceBiotech

Adimab CEO Tillman Gerngross wants to challenge the way governments the world over handle the R&D response to a frightening viral outbreak. And the Dartmouth professor is using a technology he's intimately familiar with to make his case.

Innovation and delivery are the keys to untapped ophthalmology space

Jennifer Boggs / BioWorld

Despite the appeal of shorter development timelines – and the potential of a multibillion-dollar market – ophthalmology drug development has lagged behind work in other disease areas in terms of new targets, biomarker development and even the number of players operating in the space.

The supply & demand economics behind the current VC boom and crunch

Adley Bowden / PitchBook Blog

Overnight it seems the venture industry has ground to a standstill. The ‘unicorn’ term now means overly inflated valuation in the process of negotiating a down round. The daily news is now full of departing CEOs, layoffs, zombie unicorns and who’s next punditry. How did this all happen and with such speed? Is there an economic model that can explain the boom and bust of this complex market?

Instagram updates could help pharma tap new audiences--and maybe get creative, too

Emily Wasserman / FiercePharmaMarketing

Pharma brand managers celebrated earlier this year when Twitter proposed a 10,000-character limit. But new changes to Instagram could give pharma marketers even more of a boost, one industry marketing expert said, as companies harness the platform's updated features to tap in to new audiences.

China renews consolidation drive for drug manufacture, wants TCM push

Matthew Driskill / FiercePharmaAsia

China's leadership renewed a drive to winnow out bad quality drug manufacturers and improve safety as part of a State Council meeting that updated on an ambitious program of healthcare reforms calling for access to newer therapies and greater use of traditional Chinese medicines (TCM).

19 February 2016

Groundbreaking STI test can detect chlamydia in 30 minutes

The Telegrah / Lifestyle

The Atlas io system was created by the University of Bath's spin-off biotech company Atlas Genetics in 2005. It has now won approval from the EU to be sold. The development means that patients can be tested and treated for the disease within a single clinic visit.

With pricing power waning, time for Big Pharma to become a lean, mean, well-oiled machine

Carly Helfand / FiercePharma

Waiting for the halcyon days when drugmakers could price drugs without pushback to return? Don't, GlaxoSmithKline ($GSK) U.S. pharma president Jack Bailey says. You'd be better off cutting costs instead.

Got plenty of cash? Market carnage sets up a Darwinian showdown in biotech

John Carroll / FierceBiotech

These days, when you talk to a biotech CEO, it's not unusual for the conversation to turn to just how much cash they have in the bank, and just how far out that runway extends in covering costs.

China push to bring biotech talent home is paying off

Matthew Driskill / FiercePharmaAsia

China's output of academic papers in the biotech realm has grown in volume and quality over nearly a decade as efforts to lure Chinese talent in the biotech industry back home pays off.

The Staying Power of Emerging Markets

William Looney / PhamExec.com

Whatever used to be wrong with the world of big Pharma could be fixed with a single tag phrase: emerging country markets. Most of the majors have invested heavily in this geographic segment, and the biggest of the big—companies like Novartis—now rely on it for more than a quarter of their global sales. Like all good things, however, there are shadows amidst the sunlight, and the task of turning volume sales into sustainable profits is getting harder. Economic growth in these markets is fading as commodity prices ditch in tandem with capital flight and a rising public and private debt burden. Local governance challenges are adding to the risk of building the reputation essential to securing commercial rewards.